Evidence map›Paper›PMID 40276377›Full record

ArticleClinical ophthalmology (Auckland, N.Z.)2025

Real-World Outcomes of Combined Phacoemulsification and STREAMLINE

Joseph Stanke, Don Nguyen

Abstract read
In one paragraph

Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Joseph StankeHealth Sciences Center College of Medicine, University of Oklahoma, Oklahoma City, OK, USA.ORCID 0009-0003-2115-923X
Don NguyenBVA Advanced Eye Care, Oklahoma City, OK, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To report the clinical outcomes of a novel ab interno minimally invasive procedure with the STREAMLINE Methods: In a retrospective analysis of all consecutive cases performed and followed for up to 12 months, 51 eyes of 51 subjects with mild, moderate, and severe primary open-angle glaucoma (POAG) underwent canaloplasty and incisional goniotomy following phacoemulsification cataract extraction. The procedure was performed according to the manufacturer's instructions for use. However, in contrast to other studies where the technique involved solely incisional goniotomy during viscoelastic delivery, in this study, a 1-2 clock hour goniotomy was created with the cannula after 3-6 injections of viscoelastic into Schlemm's canal. Outcomes in this interim analysis included mean reduction in IOP and medications through month 12, as well as the proportion of eyes achieving IOP reduction ≥20% from baseline. Results: Mean preoperative IOP was 16.9 mmHg using a mean of 1.2 medications (n = 51). At 30 days post-op, mean IOP was 15.3 mmHg using a mean of 0.2 medications; 21.6% (11/51) had IOP reduction ≥20% from baseline; 90.2% (46/51) were medication-free. At 6 months post-op, mean IOP was 15.6 mmHg using a mean of 0.2 medications; 21.6% (11/51) had IOP reduction ≥20% from baseline; 90.2% (46/51) were medication-free. At 12 months post-op, mean IOP was 17.0 mmHg using a mean of 0.2 medications, 37.3% (19/51) had IOP reduction ≥20% from baseline; 88.2% (45/51) were medication-free. No adverse events were reported. No secondary surgical interventions were required in any patient. Conclusion: Canaloplasty and incisional goniotomy combined with phacoemulsification safely and effectively reduced dependence on IOP-lowering medications while adequately managing IOP in eyes with primary open-angle glaucoma through 12 months of follow-up.

Indexed as

canaloplastyglaucomagoniotomyMIGStrabecular meshworkviscodilation

Identifiers

PMID40276377
PMCPMC12019685

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.